FDA approves Amgen's Prolia for new use
(Reuters) - Amgen Inc, the world's largest biotechnology company, said U.S. health regulators approved its Prolia injection for a new use as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.
People suffering from osteoporosis experience severe weakening and thinning of bones.
Prolia currently has U.S. approval to treat postmenopausal women with osteoporosis at high risk for fracture. The drug brought in sales of $120 million to Amgen between April and June, up 36 percent sequentially.
According to the National Osteoporosis Foundation, two million men in the U.S. have osteoporosis and another 12 million are at risk, Amgen said in a statement.
(Reporting by Zeba Siddiqui in Bangalore)
- Tweet this
- Share this
- Digg this
- UPDATE 4-Cricket-Australia push England to the wall in second test
- Ukraine protesters fell Lenin statue in challenge to Yanukovich
- Insight - Family, politicians battle over 'Brand Mandela'
- Thai PM proposes referendum on her future as protesters prepare big push
- Ukrainian protesters topple Lenin statue in Kiev